Atrial Fibrillation Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Powered by
All the vital news, analysis, and commentary curated by our industry experts.
Atrial fibrillation pipeline market research report provides comprehensive information on the therapeutics under development for Atrial Fibrillation, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Atrial Fibrillation and features dormant and discontinued projects.
Key Targets in the Atrial Fibrillation Pipeline Market
The key targets in the atrial fibrillation pipeline market are Potassium Channel, Sodium Channel, Calcium Channel, Beta 1 Adrenergic Receptor, Coagulation Factor X, Coagulation Factor XI, and Muscarinic Gated Atrial Potassium Channel. Potassium Channel has the highest number of pipeline products in the atrial fibrillation pipeline market.
Atrial Fibrillation Pipeline Market, by Targets
For more target insights, download a free report sample
Key MoA in the Atrial Fibrillation Pipeline Market
The key MoA in the atrial fibrillation pipeline market are Potassium Channel Blocker, Sodium Channel Blocker, Calcium Channel Blocker, Beta 1 Adrenergic Receptor Antagonist, Coagulation Factor X Inhibitor, and Coagulation Factor XI Inhibitor. Potassium Channel Blocker has the highest number of pipeline products.
Atrial Fibrillation Pipeline Market, by MoA
For more MoA insights, download a free report sample
Key RoA in the Atrial Fibrillation Pipeline Market
The key RoA in the atrial fibrillation pipeline market are oral, intravenous, inhalational, intracardiac, intramuscular, nasal, parenteral, and subcutaneous. Oral has the highest number of pipeline products.
Atrial Fibrillation Pipeline Market, by RoA
For more RoA insights, download a free report sample
Key Molecule Types in the Atrial Fibrillation Pipeline Market
The key molecule types in the atrial fibrillation pipeline market are small molecule, gene therapy, protein, monoclonal antibody. Small molecule has the highest number of pipeline products.
Atrial Fibrillation Pipeline Market, by Molecule Types
For more molecule type insights, download a free report sample
Key Companies in the Atrial Fibrillation Pipeline Market
The key companies in the atrial fibrillation pipeline market are Correvio Pharma Corp, Daiichi Sankyo Co Ltd, Nissan Chemical Corp, Toa Eiyo Ltd, AbbVie Inc, Acesion Pharma Aps, and Aetas Pharma Co Ltd. Correvio Pharma Corp has the highest number of pipeline products.
Atrial Fibrillation Pipeline Market, by Companies
To know more about companies, download a free report sample
Market report overview
Key targets | Potassium Channel, Sodium Channel, Calcium Channel, Beta 1 Adrenergic Receptor, Coagulation Factor X, Coagulation Factor XI, and Muscarinic Gated Atrial Potassium Channel |
Key MoA | Potassium Channel Blocker, Sodium Channel Blocker, Calcium Channel Blocker, Beta 1 Adrenergic Receptor Antagonist, Coagulation Factor X Inhibitor, and Coagulation Factor XI Inhibitor |
Key RoA | Oral, Intravenous, Inhalational, Intracardiac, Intramuscular, Nasal, Parenteral, and Subcutaneous |
Key molecule types | Small Molecule, Gene Therapy, Protein, Monoclonal Antibody |
Key companies | Correvio Pharma Corp, Daiichi Sankyo Co Ltd, Nissan Chemical Corp, Toa Eiyo Ltd, AbbVie Inc, Acesion Pharma Aps, and Aetas Pharma Co Ltd |
Scope
- The pipeline guide provides a snapshot of the global therapeutic landscape of Atrial Fibrillation (Cardiovascular).
- The pipeline guide reviews pipeline therapeutics for Atrial Fibrillation (Cardiovascular) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Atrial Fibrillation (Cardiovascular) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Atrial Fibrillation (Cardiovascular) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Atrial Fibrillation (Cardiovascular)
Reasons to Buy
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Atrial Fibrillation (Cardiovascular).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Atrial Fibrillation (Cardiovascular) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Acesion Pharma Aps
Aetas Pharma Co Ltd
AnaBios Corp
Anthos Therapeutics Inc
ARCA biopharma Inc
Armaron Bio Pty Ltd
Bayer AG
Bristol-Myers Squibb Co
Chaperone Pharma BV
Chong Kun Dang Pharmaceutical Corp
Correvio Pharma Corp
Daiichi Sankyo Co Ltd
Espero BioPharma Inc
FB HRS LLC
G3 Pharmaceuticals Inc
Hanmi Pharmaceuticals Co Ltd
HUYA Bioscience International LLC
Hyloris Pharmaceuticals SA
InCarda Therapeutics Inc
Inomagen Therapeutics Inc
Merck & Co Inc
Merz Pharma GmbH & Co KgaA
Milestone Pharmaceuticals Inc
Nissan Chemical Corp
Novartis AG
Rithim Biologics Inc
The Geneva Biotech Center SA
Toa Eiyo Ltd
Verseon Corp
Vivasc Therapeutics Inc
Table of Contents
Table
Figures
Frequently asked questions
-
What are the key targets in the atrial fibrillation pipeline market?
The key targets in the atrial fibrillation pipeline market are Potassium Channel, Sodium Channel, Calcium Channel, Beta 1 Adrenergic Receptor, Coagulation Factor X, Coagulation Factor XI, and Muscarinic Gated Atrial Potassium Channel.
-
What are the key MoA in the atrial fibrillation pipeline market?
The key MoA in the atrial fibrillation pipeline market are Potassium Channel Blocker, Sodium Channel Blocker, Calcium Channel Blocker, Beta 1 Adrenergic Receptor Antagonist, Coagulation Factor X Inhibitor, and Coagulation Factor XI Inhibitor.
-
What are the key RoA in the atrial fibrillation pipeline market?
The key RoA in the atrial fibrillation pipeline market are oral, intravenous, inhalational, intracardiac, intramuscular, nasal, parenteral, and subcutaneous.
-
What are the key molecule types in the atrial fibrillation pipeline market?
The key molecule types in the atrial fibrillation pipeline market are small molecule, gene therapy, protein, monoclonal antibody.
-
What are the key companies in the atrial fibrillation pipeline market?
The key companies in the atrial fibrillation pipeline market are Correvio Pharma Corp, Daiichi Sankyo Co Ltd, Nissan Chemical Corp, Toa Eiyo Ltd, AbbVie Inc, Acesion Pharma Aps, and Aetas Pharma Co Ltd.
Get in touch to find out about multi-purchase discounts
reportstore@globaldata.com
Tel +44 20 7947 2745
Every customer’s requirement is unique. With over 220,000 construction projects tracked, we can create a tailored dataset for you based on the types of projects you are looking for. Please get in touch with your specific requirements and we can send you a quote.